Saturday 17 October 2026
Export RVLP’s income statement to Excel — free account
RVL Pharmaceuticals PLC
RVLP Healthcare Biotechnology
RVL Pharmaceuticals PLC’s revenue for fiscal 2022 (year ended December 2022) was $49.7 million.
Follow RVLP
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Trend | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2023–2025 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 414 | 466 | 379 | 302 | 156 | 125 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.59 | 0.57 | 0.63 | 0.09 | 0.11 | 0.40 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 218 | 246 | 264 | 240 | 28 | 18 | 50 | ||||
| Gross margin, % | — | — | — | 42.50 | 49.06 | 46.88 | 53.49 | 88.14 | 79.33 | 80.98 | |||||
| EBT | — | — | — | (52) | (86) | (119) | (298) | (95) | (83) | (52) | |||||
| EBT margin, % | — | — | — | (23.83) | (34.85) | (45.00) | (124.16) | (341.46) | (471.60) | (104.00) | |||||
| Net income | — | — | — | (42) | (41) | (110) | (271) | (80) | (65) | (52) | |||||
| Depreciation | — | — | — | 45 | 119 | 186 | 341 | 94 | 18 | 17 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 218.46 | 5.73 | 5.82 | 4.58 | 0.46 | 0.26 | 0.55 | ||||
| Earnings | — | — | — | (41.82) | (0.96) | (2.42) | (5.17) | (1.31) | (0.96) | (0.58) | |||||
| Cash flow | — | — | — | (44.79) | 1.35 | 0.83 | 0.64 | 0.29 | (0.81) | (0.42) | |||||
| Capex | — | — | — | (15.93) | (0.16) | (0.09) | (0.08) | (0.05) | (0.03) | (0.01) | |||||
| Free cash flow | — | — | — | (60.72) | 1.19 | 0.74 | 0.57 | 0.24 | (0.84) | (0.43) | |||||
| Book value | — | — | — | 465.21 | 10.17 | 8.48 | 2.19 | 1.55 | 1.14 | 0.57 | |||||
| Shares, m | — | — | — | 1 | 43 | 45 | 52 | 61 | 67 | 90 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | 1.39 | 1.39 | 1.33 | 1.53 | 3.41 | 4.99 | 2.08 | |||||
| P/B | — | — | — | 0.84 | 0.84 | 0.91 | 3.19 | 2.75 | 1.14 | 2.02 | |||||
| EV/Sales | — | — | — | 2.52 | 2.52 | 2.08 | 2.25 | 4.82 | 5.32 | 2.33 | |||||
| EV/FCF | — | — | — | 24.13 | 24.13 | 16.42 | 18.24 | 25.26 | (1.65) | (3.00) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (45) | 58 | 38 | 34 | 18 | (55) | (38) | ||||
| Capex | — | — | — | (16) | (7) | (4) | (4) | (3) | (2) | (1) | |||||
| Free cash flow | — | — | — | (61) | 51 | 33 | 30 | 14 | (57) | (39) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | (24) | (10) | 58 | 97 | 117 | 39 | 37 | ||||
| Total debt | — | — | — | 329 | 321 | 269 | 270 | 221 | 46 | 57 | |||||
| Net debt | — | — | — | 309 | 286 | 198 | 174 | 107 | 6 | 12 | |||||
| Shareholders’ equity | — | — | — | 465 | 436 | 384 | 115 | 94 | 77 | 51 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (4.41) | (4.33) | (12.79) | (43.04) | (19.08) | (25.18) | (37.84) | ||||
| ROIC | — | — | — | (2.59) | (4.51) | (10.59) | (60.70) | (28.25) | (62.69) | (58.06) | |||||
| ROE | — | — | — | (9.28) | (9.13) | (26.76) | (108.67) | (76.32) | (76.11) | (80.88) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Jun 2023
Charts ten years each
RVL Pharmaceuticals PLC vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DARE Dare Bioscience, Inc. | $14.6M | — (loss-making) | — (loss-making) | +984.43% (above 0%: growing) | n/m | −30.23% (below 0%: shrinking) | (70.56%) | (1,582.93%) | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | — (loss-making) | — (loss-making) | −89.33% (below 0%: shrinking) | n/m | −174.72% (below 0%: shrinking) | 81.71% | (221.45%) | Compare |
| CNSY Cerenome, Inc. | $14.3M | — (loss-making) | — (loss-making) | −70.43% (below 0%: shrinking) | n/m | −31.46% (below 0%: shrinking) | 100.00% | (2,203.65%) | Compare |
| TVRD Tvardi Therapeutics, Inc. | $14.3M | — (loss-making) | — (loss-making) | +20.33% (above 0%: growing) | n/m | −57.26% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLVSQ Clovis Oncology, Inc. | $14.2M | — (loss-making) | — (loss-making) | −19.13% (below 0%: shrinking) | n/m | +11.83% (above 0%: growing) | 71.93% | (144.26%) | Compare |
| BCDA BioCardia, Inc. | $14.2M | — (loss-making) | — (loss-making) | −93.02% (below 0%: shrinking) | n/m | −5.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RVLP RVL Pharmaceuticals PLC | $14.1M | — (loss-making) | — (loss-making) | −2.25% (below 0%: shrinking) | n/m | −734.24% (below 0%: shrinking) | 76.43% | (266.66%) | |
| LPCN Lipocine Inc. | $13.9M | — (loss-making) | — (loss-making) | −69.48% (below 0%: shrinking) | n/m | −60.56% (below 0%: shrinking) | 100.00% | (1,495.11%) | Compare |
| KTTA Pasithea Therapeutics Corp. | $13.7M | — (loss-making) | — (loss-making) | +1,494.04% (above 0%: growing) | n/m | −21.68% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $14.3M | — | — | −44.30% | — | −30.84% | 90.86% | (182.86%) |
RVL Pharmaceuticals PLC (RVLP) key facts
- RVL Pharmaceuticals PLC (RVLP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- RVL Pharmaceuticals PLC’s revenue for fiscal 2022 (year ended December 2022) was $49.7 million.
- Return on equity was −80.9% and debt-to-equity 3.54.
- Its Piotroski F-score is 3 out of 9 for fiscal 2022.
RVL Pharmaceuticals PLC (RVLP) Latest News
No news at this impact. Lower the threshold for more.